The 2020 US presidential election looks set to stand the test of time as one of the most critical votes for the American people.


In addition to deciding the immediate future of the country, this election has many potential ramifications when it comes to the cannabis industry.

The fractured state of the US cannabis space has prevented a free-flowing market from flourishing, and has left policy and banking regulations on the back burner.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

The decision between four more years of Donald Trump or a new president in Joe Biden may determine the federal standing of cannabis, and there are state-by-state decisions on the docket as well.

While Biden has expressed concerns about cannabis and what he considers a lack of research geared at disproving commonly believed views on its effects, his running mate Kamala Harris has spoken positively about the drug. It is expected that if the Democrats takes the White House they will have a more favorable view on cannabis, its medical benefits and the business surrounding it.

For his part, Trump has been a mixed bag when it comes to cannabis. Jeff Sessions, his first appointed attorney general, mounted what seemed to be a campaign against the burgeoning industry at the state level. Sessions was later removed from his post, leaving a nebulous federal view on the drug.

Even so, cannabis has thrived in the US due to the development of state markets that have legalized medical or recreational cannabis sales. They have allowed the licensing of growing facilities and the development of novel regulated products like vape pens and edibles.

Thanks to the opening of these state markets, various companies have reached investors with the promise of modern commerce options with steady sales and widespread dispensary networks.

These companies have adopted the multi-state operator (MSO) moniker given that they must build operations from the ground up in each state they enter, whether it is via an acquisition or organically.

2020 has been good for MSOs, which have grown from being an alternative marijuana investment to the dominant type of cannabis company in the market — at least according to one financial expert.

“The US is a much bigger market, a much better market, and now this year the US market is performing a lot better than most of the Canadian market," said Dan Ahrens, managing director and chief operating officer at AdvisorShares, and the active manager for the AdvisorShares Pure Cannabis ETF (ARCA: YOLO) and the AdvisorShares Pure US Cannabis ETF (ARCA:MSOS).

Cannabis investors will have to keep a close eye on the results of the US presidential election as it may signify a new era for the industry. Click through to the links below to read more:

Don't forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

Will Trump or Biden win the fast-approaching US presidential election? And which candidate would be better...

What Happens to Cannabis if Trump Wins?

INN checked in with experts in the industry to investigate the path the cannabis business may...

What Happens to Cannabis if Biden Wins?

INN checked in with experts in the industry to investigate how the cannabis business could change...

Which States are Voting on Cannabis in...

As the US cannabis market develops, these five states are inching closer to legalizing the drug...

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less

Part of “Rooted in Good” CSR Platform, “Feed the Block” Gives Back Through Strategic Social Partnerships with Local Organizations Focused on Food Insecurity

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced a multi-state fundraising initiative in which proceeds will benefit 24 locally run food banks, homeless shelters and nonprofits working to proactively address the needs of those facing food insecurity in communities across America. This effort is a part of the Strategic Social Partnerships pillar within Curaleaf’s “Rooted in Good” Corporate Social Responsibility platform.

Keep reading... Show less

On September 8, 2020, Aurora Cannabis Inc. (NYSE:ACB) stunned the market when it announced that it expected to record up to $1.8 billion in goodwill impairment charges in the fourth quarter of 2020. On the same day, Aurora also announced a charge of approximately $140 million in the carrying value of certain inventory, and that it was appointing a new chief executive officer. On this news, Aurora’s stock fell approximately 11.6% in just one day. Since May 2020, Aurora’s stock is down approximately $10.00 per share

A lawsuit alleging violations of federal securities laws has been filed against Aurora and certain of its officers and directors. The suit alleges, among other things, that Aurora misled investors as to the value of prior acquisitions, that the Company had experienced degradation in certain assets, and that as a result, it was foreseeable that Aurora would record significant goodwill and asset impairment charges. According to the lawsuit, this news was so shocking because Aurora had previously lauded a “business transformation plan” that would purportedly “better align the business financially with the current realities of the cannabis market.”

Keep reading... Show less

  • Exclusive patent licensed from University of Idaho.
  • Mustard-derived fumigation of stored food – targeting vegetables and potatoes.
  • Leading agrochemical for sprout suppression – chlorpropham – banned by European Union on Oct. 8, 2020.
  • Appointment of Scientific Advisor Dr. Matthew J. Morra, professor emeritus of soil biochemistry at University of Idaho.

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce the exclusive patent licensing from the University of Idaho pertaining to a natural biopesticide mustard-based treatment of stored produce and other foods, particularly sprout suppression of potatoes.

Keep reading... Show less

Study represents the first research completed on the long-term toxicity and lifespan effects of cannabidiol in the preclinical model C. elegans

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) and its medical division, Spectrum Therapeutics, have completed and published a new study on the long-term effects of cannabidiol (CBD), specifically focusing on toxicity and lifespan effects of CBD in the preclinical model C. elegans.

Keep reading... Show less